Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Intangibles (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Intangibles for 3 consecutive years, with $150.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Intangibles changed 0.0% to $150.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $150.6 million, a 0.0% change, with the full-year FY2024 number at $150.6 million, changed 0.0% from a year prior.
  • Intangibles was $150.6 million for Q3 2025 at Cartesian Therapeutics, roughly flat from $150.6 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $150.6 million in Q4 2023 to a low of $150.6 million in Q4 2023.
  • A 3-year average of $150.6 million and a median of $150.6 million in 2023 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 0.0% in 2024; the steepest drop was 0.0% in 2024.
  • Cartesian Therapeutics' Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then changed by 0.0% to $150.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Intangibles are $150.6 million (Q3 2025), $150.6 million (Q4 2024), and $150.6 million (Q3 2024).